# 0 GI haemorrhage

**Page range:** 25â€“25

```text
0
GI haemorrhage
0
1(1%)
Acute kidney injury
0
1(1%)
Note: Percentages are based on N. MedDRA Version 27.0.
NOS: Not Otherwise Specified
Clinical Output Source:
root/clinical_studies/RO7499790/CDT30380/BO42864/data_analysis/Adhoc_Analysis/prod/output/t_ae_ct
c_MAIN_SE.out
The analysis of both the study arms was performed in relevance to infection related AEs.
Table 5 summarizes the distribution of Grade 3-5 infection AEs by MedDRA PT in
pralsetinib treatment arm and comparator arm.
Table 5
Distribution of Grade 3-5 Infection AEs by MedDRA Preferred
Term in Pralsetinib Treatment Arm and Standard of Care Arm of
the AcceleRET-Lung study
Adverse Events
MedDRA PT
Pralsetinib Treated Arm
(N=108)
Standard of Care
(N=104)
Grade 3-4 (%)
Grade 5 (%)
Grade 3-4 (%)
Grade 5 (%)
COVID-19
0
0
1 (1.0)
```